Annual Report to the Nation on the Status of Cancer

Annual Report to the Nation on the Status of Cancer

Annual Report to the Nation

We are pleased to announce the release of the latest Annual Report to the Nation on the Status of Cancer. The Annual Report to the Nation on the Status of Cancer represents a collaborative effort from senior researchers at ACS, CDC, NAACCR, and NCI to produce current and comprehensive trends in cancer incidence and mortality. Our 23rd Report was led by ACS and is currently available as an on-line pre-publication copy.

The purpose of this report is to produce the most up-to-date and comprehensive trends in cancer incidence and mortality. Each year we also focus on a special topic. This year we produced two reports: Part I focuses on national statistics and Part II focuses on our the economic burden associated with cancer care.

The Annual Report to the Nation is a collaborative endeavor by leaders in the cancer surveillance field. Each year representatives from the American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, National Center for Health Statistics, NAACCR, and invited scientists analyze the latest cancer rates from NAACCR and other sources to report on the most recent cancer trends in the US. A special focus on a cancer of interest is selected annually for in-depth analysis. These reports are published in scientific journals.

 

ANNUAL REPORT TO THE NATION PART ONE:

Paper titled “Annual Report to the Nation on the Status of Cancer” It is a 2-part report; Part I is focused on cancer incidence and mortality patterns in the United States. The report shows death rates continue to decline overall and for many cancer types, with the decline accelerated for lung cancer and melanoma during the most recent period. For several other major cancers, however, death rates continue to increase or previous declines in rates have slowed or ceased. Also, overall incidence rates continue to increase among females, children, and adolescents and young adults. These findings inform efforts related to prevention, early detection, and treatment and for broad and equitable implementation of effective interventions, especially among under-resourced populations.  

 

HIGHLIGHTS FROM ARN Part I:

  • Cancer death rates continued to decline in men, women, adolescents and young adults, and children in the United States from 2001 to 2018.
  • Decreases were seen in men and women in all major racial and ethnic groups.
  • Cancer incidence rates remained stable among men from 2013 to 2017 and increased slightly for women from 2003 to 2017.
  • Two-year survival for advanced melanoma of the skin has substantially improved since 2009, followed by significant declines in melanoma death rates since 2013 in men and 2012 in women.

 

ANNUAL REPORT TO THE NATION PART TWO:

The “Annual Report to the Nation on the Status of Cancer” It is a 2-part report. Part II is focused on the out-of-pocket economic burden of cancer. This report is the most comprehensive examination of patient economic burden for cancer care to date and includes information on patient out-of-pocket spending. While this analysis is about the costs that are directly incurred, which are of critical importance to patients and their families, the total overall costs of cancer care and lost productivity in the United States are much larger.

 

HIGHLIGHTS FROM THE REPORTS Part II:

Across all cancer sites, out-of-pocket expenses variable by the stage of diagnosis of a patient’s caner. Average patient out-of-pocket costs for medical services in the initial and end-of-life phases of care were lowest for patients originally diagnosed with localized disease compared with more advanced stage disease.​ And there was also substantial variation in the economic burden of out-of-pocket costs by cancer type, which reflects differences in treatment intensity and duration as well as length of survival. Cancer is a significant financial burden even among insured patients.  In 2019, national out-of-pocket costs for the most common cancers were: breast–$3.14 billion, prostate– $2.26 billion, colorectal– $1.46 billion, and lung–$1.35 billion.

Copyright © 2018 NAACCR, Inc. All Rights Reserved | naaccr-swoosh-only See NAACCR Partners and Sponsors